Tag: Selinexor

According to a pooled analysis of clinical trial data, some of the most common adverse events associated with selinexor treatment for multiple myeloma include gastrointestinal issues and a significant reduction in platelet counts. Understanding **what are the side effects of selinexor for myeloma** is crucial for patients and caregivers to manage treatment and maintain quality of life effectively.

Approved by the FDA in 2019, selinexor is a first-in-class, oral selective inhibitor of nuclear export (SINE) used to treat specific blood cancers. The generic name for this medication is selinexor, but what is selinexor also known as, and what makes its mechanism of action so unique? This article details its various names and its targeted approach to cancer treatment.

Selinexor (Xpovio), a first-in-class oral selective inhibitor of nuclear export (SINE), was granted accelerated FDA approval in 2019 for the treatment of certain hematological malignancies. But what is selinexor, and how does this innovative drug fight cancer cells?